284 related articles for article (PubMed ID: 26177019)
1. Gastrointestinal pH and Transit Time Profiling in Healthy Volunteers Using the IntelliCap System Confirms Ileo-Colonic Release of ColoPulse Tablets.
Maurer JM; Schellekens RC; van Rieke HM; Wanke C; Iordanov V; Stellaard F; Wutzke KD; Dijkstra G; van der Zee M; Woerdenbag HJ; Frijlink HW; Kosterink JG
PLoS One; 2015; 10(7):e0129076. PubMed ID: 26177019
[TBL] [Abstract][Full Text] [Related]
2. ColoPulse tablets perform comparably in healthy volunteers and Crohn's patients and show no influence of food and time of food intake on bioavailability.
Maurer JM; Schellekens RC; van Rieke HM; Stellaard F; Wutzke KD; Buurman DJ; Dijkstra G; Woerdenbag HJ; Frijlink HW; Kosterink JG
J Control Release; 2013 Dec; 172(3):618-24. PubMed ID: 24096020
[TBL] [Abstract][Full Text] [Related]
3. Oral ileocolonic drug delivery by the colopulse-system: a bioavailability study in healthy volunteers.
Schellekens RC; Stellaard F; Olsder GG; Woerdenbag HJ; Frijlink HW; Kosterink JG
J Control Release; 2010 Sep; 146(3):334-40. PubMed ID: 20621586
[TBL] [Abstract][Full Text] [Related]
4. Development of novel zero-order release budesonide tablets for the treatment of ileo-colonic inflammatory bowel disease and comparison with formulations currently used in clinical practice.
Gareb B; Dijkstra G; Kosterink JGW; Frijlink HW
Int J Pharm; 2019 Jan; 554():366-375. PubMed ID: 30414898
[TBL] [Abstract][Full Text] [Related]
5. A novel coating concept for ileo-colonic drug targeting: proof of concept in humans using scintigraphy.
Varum FJ; Hatton GB; Freire AC; Basit AW
Eur J Pharm Biopharm; 2013 Aug; 84(3):573-7. PubMed ID: 23348235
[TBL] [Abstract][Full Text] [Related]
6. A novel double-coating approach for improved pH-triggered delivery to the ileo-colonic region of the gastrointestinal tract.
Liu F; Moreno P; Basit AW
Eur J Pharm Biopharm; 2010 Feb; 74(2):311-5. PubMed ID: 19932177
[TBL] [Abstract][Full Text] [Related]
7. Investigation of pH and Temperature Profiles in the GI Tract of Fasted Human Subjects Using the Intellicap(®) System.
Koziolek M; Grimm M; Becker D; Iordanov V; Zou H; Shimizu J; Wanke C; Garbacz G; Weitschies W
J Pharm Sci; 2015 Sep; 104(9):2855-63. PubMed ID: 25411065
[TBL] [Abstract][Full Text] [Related]
8. A new oral formulation for the release of sodium butyrate in the ileo-cecal region and colon.
Roda A; Simoni P; Magliulo M; Nanni P; Baraldini M; Roda G; Roda E
World J Gastroenterol; 2007 Feb; 13(7):1079-84. PubMed ID: 17373743
[TBL] [Abstract][Full Text] [Related]
9. Analysis of small intestinal transit and colon arrival times of non-disintegrating tablets administered in the fasted state.
Pišlar M; Brelih H; Mrhar A; Bogataj M
Eur J Pharm Sci; 2015 Jul; 75():131-41. PubMed ID: 25769525
[TBL] [Abstract][Full Text] [Related]
10. Validation of the IntelliCap® system as a tool to evaluate extended release profiles in human GI tract using metoprolol as model drug.
Söderlind E; Abrahamsson B; Erlandsson F; Wanke C; Iordanov V; von Corswant C
J Control Release; 2015 Nov; 217():300-7. PubMed ID: 26385166
[TBL] [Abstract][Full Text] [Related]
11. Assessment of levetiracetam bioavailability from targeted sites in the human intestine using remotely activated capsules and gamma scintigraphy: Open-label, single-dose, randomized, four-way crossover study in healthy male volunteers.
Stockis A; Sargentini-Maier ML; Otoul C; Connor A; Wilding I; Wray H
Clin Ther; 2010 Sep; 32(10):1813-21. PubMed ID: 21194605
[TBL] [Abstract][Full Text] [Related]
12. In vivo evaluation of a novel pH- and time-based multiunit colonic drug delivery system.
Bott C; Rudolph MW; Schneider AR; Schirrmacher S; Skalsky B; Petereit HU; Langguth P; Dressman JB; Stein J
Aliment Pharmacol Ther; 2004 Aug; 20(3):347-53. PubMed ID: 15274672
[TBL] [Abstract][Full Text] [Related]
13. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
Chen C; Bujanover S; Kareht S; Rapoport AM
Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
[TBL] [Abstract][Full Text] [Related]
14. Interplay between intestinal pH, transit time and feed status on the in vivo performance of pH responsive ileo-colonic release systems.
Ibekwe VC; Fadda HM; McConnell EL; Khela MK; Evans DF; Basit AW
Pharm Res; 2008 Aug; 25(8):1828-35. PubMed ID: 18465212
[TBL] [Abstract][Full Text] [Related]
15. Gastrointestinal transit, release and plasma pharmacokinetics of a new oral budesonide formulation.
Brunner M; Ziegler S; Di Stefano AF; Dehghanyar P; Kletter K; Tschurlovits M; Villa R; Bozzella R; Celasco G; Moro L; Rusca A; Dudczak R; Müller M
Br J Clin Pharmacol; 2006 Jan; 61(1):31-8. PubMed ID: 16390349
[TBL] [Abstract][Full Text] [Related]
16. Development of a zero-order sustained-release tablet containing mesalazine and budesonide intended to treat the distal gastrointestinal tract in inflammatory bowel disease.
Gareb B; Eissens AC; Kosterink JGW; Frijlink HW
Eur J Pharm Biopharm; 2016 Jun; 103():32-42. PubMed ID: 27000751
[TBL] [Abstract][Full Text] [Related]
17. An in vivo comparison of intestinal pH and bacteria as physiological trigger mechanisms for colonic targeting in man.
McConnell EL; Short MD; Basit AW
J Control Release; 2008 Sep; 130(2):154-60. PubMed ID: 18639950
[TBL] [Abstract][Full Text] [Related]
18. An investigation into the in vivo performance variability of pH responsive polymers for ileo-colonic drug delivery using gamma scintigraphy in humans.
Ibekwe VC; Liu F; Fadda HM; Khela MK; Evans DF; Parsons GE; Basit AW
J Pharm Sci; 2006 Dec; 95(12):2760-6. PubMed ID: 16917845
[TBL] [Abstract][Full Text] [Related]
19. Pulsatile drug delivery to ileo-colonic segments by structured incorporation of disintegrants in pH-responsive polymer coatings.
Schellekens RC; Stellaard F; Mitrovic D; Stuurman FE; Kosterink JG; Frijlink HW
J Control Release; 2008 Dec; 132(2):91-8. PubMed ID: 18775755
[TBL] [Abstract][Full Text] [Related]
20. A non-invasive, low-cost study design to determine the release profile of colon drug delivery systems: a feasibility study.
Maurer MJ; Schellekens RC; Wutzke KD; Dijkstra G; Woerdenbag HJ; Frijlink HW; Kosterink JG; Stellaard F
Pharm Res; 2012 Aug; 29(8):2070-8. PubMed ID: 22422322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
